RevOpsis VC Trigger: CDMO & CTMS Pipeline Play

🚀 Battle Card: RevOpsis Therapeutics

• Dr. Ram Bhandari, CEO 📧 rbhandari@revopsis.com

• This RevOpsis Therapeutics sales trigger spotlights a fresh VC infusion to accelerate next-gen ophthalmic therapy development on the Rev-Mod Platform. → Source

• Lack of scalable GMP manufacturing infrastructure for ophthalmic biologics

• Need for streamlined regulatory submissions and clinical trial management

• Primary: CDMO partnership → Rapid scale-up to GMP production for preclinical & clinical phases

• Expansion: Clinical trial management system → Accelerate patient enrollment and real-time data insights

• HQ: San Carlos, CA

• Employees: ≈ 75

• Rev: ≈ $5 M

• Website: revopsis.com

🤼 Competitive Intel

• Catalent (catalent.com) — CDMO for ophthalmic & biologics
• Unique edge: Broad clinical supply chain support
• Evaluated by CTO & VP Manufacturing

• Lonza (lonza.com) — CDMO & GMP cell therapy
• Unique edge: Leading cell and gene therapy expertise
• Evaluated by Head of CMC

• Recipharm (recipharm.com) — API & drug-product services
• Unique edge: Global network of specialized facilities
• Evaluated by Dir. Process Dev

• Thermo Fisher Scientific (thermofisher.com) — End-to-end biomanufacturing
• Unique edge: Integrated analytical and fill-finish capabilities
• Evaluated by VP Ops & QA

• Fujifilm Diosynth Biotechnologies (fujifilm.com) — Recombinant protein & viral vector mfg
• Unique edge: High-yield suspension culture platforms
• Evaluated by Head of Bioprocess

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑CDMO partnership for rapid GMP scale-up❑
PROOF_METRIC  = ❑≈30% faster scale-up❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Ram
COMPANY     = RevOpsis Therapeutics
DEPT        = ≈ Manufacturing
SIZE        = ≈75
BOTTLENECK  = Lack of scalable GMP manufacturing infrastructure for ophthalmic biologics
EVENT       = Inks New Financing
DETAIL      = RevOpsis Therapeutics Inks New Financing
PAIN        = Lack of scalable GMP manufacturing infrastructure for ophthalmic biologics
SRC         = https://vcnewsdaily.com/revopsis-therapeutics/venture-capital-funding/vzlrwskhxr
SIM_CO      = Catalent
WIN_METRIC  = ≈30% faster scale-up
NEXT_SIZE   = ≈150
EMP_EST     = ≈75
REV_EST     = ≈$5M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈75-person ≈ Manufacturing

Ram—noticed your manufacturing team is ≈75.

That’s when Lack of scalable GMP manufacturing infrastructure for ophthalmic biologics slows growth.

We helped Catalent fix this with CDMO partnership for rapid GMP scale-up.

Result: ≈30% faster scale-up.  
Quick call?

PS—next bottleneck hits ≈150.

DM ≤45 words, TONE:
Saw your post about RevOpsis Therapeutics Inks New Financing — Lack of scalable GMP manufacturing infrastructure for ophthalmic biologics.  
CDMO partnership for rapid GMP scale-up. ≈30% faster scale-up.  
Quick chat?